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Parkinson' diseaseMitochondrial dysfunction is an important intracellular lesion associated with a wide variety of diseases
including neurodegenerative disorders. In addition to aging, oxidative stress and mitochondrial DNA
mutations, recent studies have implicated a role for the mitochondrial accumulation of proteins such as
plasma membrane associated amyloid precursor protein (APP) and cytosolic alpha synuclein in the
pathogenesis of mitochondrial dysfunction in Alzheimer's disease (AD) and Parkinson's disease (PD),
respectively. Both of these proteins contain cryptic mitochondrial targeting signals, which drive their
transport across mitochondria. In general, mitochondrial entry of nuclear coded proteins is assisted by import
receptors situated in both outer and inner mitochondrial membranes. A growing number of evidence
suggests that APP and alpha synclein interact with import receptors to gain entry into mitochondrial
compartment. Additionally, carboxy terminal cleaved product of APP, ∼4 kDa Abeta, is also transported into
mitochondria with the help of mitochondrial outer membrane import receptors. This review focuses on the
mitochondrial targeting and accumulation of these two structurally different proteins and the mode of
mechanism by which they affect the physiological functions of mitochondria.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Nature of signal sequences required for directing a protein
molecule to a speciﬁc cellular compartment have been deﬁned [1,2].
Studies for the past several decades on the protein targeting have
remarkably contributed to our understanding of mechanisms under-
lying the transport of protein molecule to a speciﬁc cellular
compartment (as reviewed in Refs # [1–11]). Recent studies have
demonstrated that several physiologically important protein mole-
cules belonging to animal and plant kingdoms also target tomore than
one compartment suggesting the presence of multiple hidden signals
in these proteins [12–26]. Studies have also suggested the need for
post translational modiﬁcations to activate these hidden signals
[13,19,21–25]. Nevertheless, we are still beginning to understand the
mechanisms involved in the activation of hidden signals during the
targeting of these proteins to multiple compartments and cellular
consequences of multiple organelle localization. Mitochondria are
vital organelles for various neuronal functions. The mitochondrion, a
double-membrane structure organelle, contains machinery for tran-
scription, translation, and ﬁve protein complexes involved in the
oxidative phosphorylation to generate adenosine triphosphate (ATP).
Each mitochondrion contains multiple copies of 16.5 kb DNA that
codes for the 13 proteins. Among 13 proteins, seven are part of
complex I, one of complex III, three of complex IV and two of complex1 215 573 6651.
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import a large number of proteins that are coded by nuclear DNA.
Recent proteomic studies suggest that over 1500 nuclear encoded
proteins are reported to be imported into mammalian mitochondria
under physiological conditions [27]. Furthermore, dysfunction of
these mitochondrial complexes is well documented during the
pathogenesis of neurodegenerative disorders [28–48]. However, the
precise cause for dysfunction of these complexes in the neurodegen-
erative disorders is not well understood. A large body of literature has
suggested an important role for a number of factors including
oxidative stress, mitochondrial DNA mutations, imbalance in calcium
homeostasis and aging in the dysfunction of mitochondrial complexes
[28–34,40,46,47]. In addition, recent studies have also implicated a
role for targeting and accumulation of plasma membrane APP and
cytosolic alpha synuclein to mitochondria in the pathogenesis of
mitochondrial dysfunction in Alzheimer's and Parkinson's diseases,
respectively [49–66]. It is not clear how APP and alpha synuclein
accumulate in the mitochondrial compartment during the pathogen-
esis of AD and PD respectively. Mitochondrial targeting of alpha
synuclein and APP is a challenging and newly emerging ﬁeld, which
may be an important contributor in understanding the mitochondrial
dysfunction in neurodegenerative disorders. This review focuses on
the role of players involved in the mitochondrial targeting of APP and
alpha synuclein and the inhibitory effects of mitochondrial accumu-
lated APP and alpha synuclein on wide varieties of mitochondrial
physiological functions resulting in the mitochondrial dysfunction as
seen in AD and PD, respectively.
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PD is the second most common progressive neurodegenerative
disorder in humans, which is associated with loss of dopaminergic
neurons in substantia nigra [67–69]. Clinically, PD is characterized by
severe motor dysfunction including uncontrollable resting tremor,
muscular rigidity, impaired postural reﬂexes, and bradykinesia. One of
the pathological hallmarks of PD and related synucleinopathies is
intracellular inclusions called lewy bodies that consist of aggregated
alpha synuclein [67–72]. Although, the physiological functions of
alpha synuclein are not clear but several lines of evidence suggest that
it may act as a chaperone that plays a role in regulating membrane
stability, neuronal plasticity and enzymatic activities [67,68,71–73].
Moreover, constitutive levels of alpha synuclein may be important for
maintaining the functional integrity of mitochondria inner membrane
complexes I and III [57,74].
Alpha synuclein exhibits dynamic structural changes based on the
local cellular conditions. Various triggering factors, either environ-
mental or genetic, can lead to a cascade of events involving misfolding
or loss of normal function of alpha synuclein [67–69,71–73,75].
Importantly, two autosomal dominant mutations (A53T), and (A30P)
and triplication of the alpha synuclein gene resulting in the increased
study state levels of synuclein were linked to familial early onset PD
[76–78]. It is thought that mutant alpha synuclein proteins tend to
aggregate more rapidly than the wild type human alpha synuclein, to
form lewy body-like intraneuronal inclusions [67–69,71,72].
Several groups have shown mitochondrial dysfunction, oxidative
stress and impairment of complex I in pathogenesis of PD [34–39].
Complex I is the largest and ﬁrst of ﬁve electron transport linked
oxidative phosphorylation complexes of mitochondria and catalyzes
the oxidation of NADH, reduction of ubiquinone to generate proton
gradient across the membrane. Defect in the function of complex I
results in the production of reactive oxygen free radicals. Mammalian
complex I is an L shaped structure consisting of 45 subunits.
Functionally, the complex I can be subdivided into three distinct
fragments. The ﬁrst part is ﬂavo mononucleotide containing NADH
dehydrogenase segment, which is exposed to matrix side of
mitochondria. The second part is iron sulfur clusters containing
membrane buried portion, which is involved in electron transfer to
the electron transporter ubiquinone. The membrane bound transpor-
ter segment is the third part of complex I, which is involved in proton
translocation. Evidence for impaired complex I mediated mitochon-
drial dysfunction in PD comes from studies using cybrids that
contained mitochondria from PD patients, which showed reduced
complex I activity [79,80]. Moreover, chronic administration of
rotenone, an inhibitor of mitochondrial complex I, to rat induced the
degeneration of tyrosine hydroxylase positive neurons in nigrostriatal
region indicating that the perturbation of mitochondrial functions
may trigger PD like symptoms [81]. Furthermore, overexpression of
either wild type or mutant alpha synuclein forms in cell culture
systems as well as in transgenic animal models is associated with
mitochondrial abnormalities, oxidative stress, and cell loss [57,59,62–
64,66]. These studies clearly demonstrate the possible relationships
among increased alpha synuclein levels, mitochondrial defects and PD
pathology in human and rodent models
3. Mitochondrial abnormalities and APP in AD models
AD is the fourth leading cause of death in the developed world.
Besides dementia, the most prominent clinicopathological features of
this disease are extracellular deposition of amyloid plaques, intracel-
lular neuroﬁbrillary tangles, synaptic and progressive neuronal
degeneration/loss [82,83]. Amyloid plaques consist of deposits of
∼4 kDa peptide called beta amyloid (Abeta), which are derived
through proteolytic processing of APP. APP occurs as 3 major isoforms
due to alternative splicing of the gene. The shortest form, APP695,lacks the serine protease inhibitor domain and occurs predominantly
in neurons while longer non-neuronal forms such as APP770 and
APP751 contain the serine protease inhibitor domain [82,53]. How-
ever, normal physiological functions of endogenous APP are not
thoroughly understood but are thought to be involved in the
stabilizing contact points between synapses and maintaining mito-
chondrial functions [51,82,84].
Decreased energy metabolism, decreased mitochondrial ﬂuidity
and decreased activity of mitochondrial cytochrome c oxidase, a 13
subunit terminal oxidase in the respiratory chain, leading to
mitochondrial dysfunction have been reported in various AD models
[33,40–45]. A growing number of studies have reported a possible
interconnection among accumulation of full length APP and its cleaved
product, especially Abeta, oxidative stress andmitochondrial dysfunc-
tion in the cellular, transgenic and humanADmodels includingDown's
syndrome patients [85–98]. Upregulation of APP, which is inﬂuenced
by aging, stress and depletion of tropic factors, is also considered to
play an important role in the cellular abnormalities including
mitochondrial dysfunction in AD [99–102]. However, the amount of
APP expression needed to bring about cellular abnormalities varies
from model to model and the presence of familial mutations in and
around abeta domain of APP [49,52,85–90,103]. Higher levels of
mutations bearing neuronal and non-neuronal forms of APP are
reported to bring about mitochondrial abnormalities faster than their
wild type counterparts [103]. Using biochemical and electron micro-
scopy techniques, studies have observed that over expression of non-
neuronal form APP751 in cultured human muscle-ﬁber cells and
mouse embryonal carcinoma (P19) cells was associated with mito-
chondrial structural abnormalities and altered mitochondrial mem-
brane potentials [88,89]. Collectively, these studies indirectly suggest
the involvement of APP in the mitochondrial dysfunction.
4. Mitochondrial import machinery
The investigations of nature of targeting signals and the interaction
with mitochondrial receptors of APP and alpha synuclein are of great
importance to understand their direct role in the mitochondrial
dysfunction. Mitochondrial targeting signals are rich in basic amino
acids, which can form amphipathic α-helices. Majority of mitochon-
drial proteins have N-terminal mitochondrial targeting signals but in
some proteins these signals can either be found at C-terminus or in the
internal part of the protein molecule [104–106]. In addition,
mitochondrial targeted proteins are required to maintain import
competent unfolded conﬁrmation to be recognized by translocases of
outer membrane (TOM). The functions of these mitochondrial import
receptors are well conserved in prokaryotic and eukaryotic organisms
[106]. Mitochondrial import signals are ﬁrst recognized by a group of
major translocases of outer membrane namely TOM 70, TOM 20 and
TOM 22 in a sequential manner. Recent study demonstrates that
TOM70 can act like a chaperone to keep proteins in import competent
conﬁrmation [107,108]. Following the recognition of signals by these
surface receptors, proteins are transported through TOM40, which is a
general import pore (GIP) forming protein [109]. Barrel forming outer
membrane proteins are further recognized by another group of
receptors called SAM (sorting and assembly machinery) complex,
which assists the insertion of these proteins in to outer membrane
[104–106,110]. Recent study has suggested that mitochondrial
translocation of some proteins including the ones with N-terminal
chimeric signals may involve by passing of outer membrane receptors
such as TOM70, 20 and 22 but not TOM40 [111,112]. Proteins that are
passed through TOM40 are further recognized by inner membrane
translocases (TIM) namely TIM22 and TIM23. TOM40 channel is
thought to be larger than TIM 22 and 23 channels. Importantly,
targeting to inner membrane receptors requires ATP as well as
mitochondrial membrane potential [104–112]. Polytypic inner mem-
brane proteins are recognized by the TIM22 complex consists of
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Matrix and inner membrane anchored mitochondrial proteins are
recognized by TIM 23 complex consists of channel forming Tim23 and
peripheral TIM17 [104–106,110]. Though many of matrix targeted
proteins contain N-terminal cleavable signals, but there are a large
number of mitochondrial proteins do not contain cleavable signals
[104,105,112].
5. Mitochondrial targeting signals of alpha synuclein and APP
5.1. Mitochondrial signals of alpha synuclein
Alpha synuclein, a 140 amino acid presynaptic soluble protein.
Prediction analyses suggest the possible presence of mitochondrial
targeting like signals [57]. In addition, the alignment of N-terminal
sequence of alpha synuclein with cleavable N-terminal mitochondrial
targeting signals of bonaﬁed mitochondrial cytochrome P450Scc
(CYP11A1) and cytochrome P450 sterol 27-hydroxylase (CYP27A1)
suggests that ﬁrst 32 amino acids of N-terminus of alpha synuclein
contains 6 positively charged amino acids (Lysine) and are capable of
forming helical structure. These properties of N-terminus of alpha
synuclein resemble the physico-chemical properties of mitochondrial
targeting sequences (Fig. 1A). However, it is unclear whether
mitochondrial targeting signals of alpha synuclein are cleaved by
matrix proteases following the intramitochondrial entry. Recent
reports including our laboratory's have observed constitutive pre-
sence of synuclein in the mitochondria from the brains of rodents and
humans [57–61]. Using biochemical and cell biological approachesFig. 1.Mitochondrial targeting signals in alpha synuclein and APP proteins. (A) Physico-che
mitochondrial targeting signals of human P40Scc and P450 c27. (B) Comparison of N-termin
hydrophobic ER targeting domain followed by the positively charged mitochondrial targetinincluding deletion constructs of alpha synuclein, Devi et al. [57] have
shown that N-terminal 32 amino acid region of alpha synuclein may
be critical for mitochondrial targeting in dopaminergic DAN neurons
and isolated mitochondria.5.2. Mitochondrial signal of APP
Unlike alpha synuclein, mitochondrial targeting signals of APP,
which are conserved in all three major forms of APP, seem to be
different and show similarities with non-cannonical chimeric signals
that are discovered and characterized by Avadhani and colleagues
[22–26]. Chimeric signals are deﬁned as the combination of
endoplasmic reticulum (ER) and mitochondrial targeting signals
arranged in tandem. These signals can localize a protein translated
from a single gene to ER andmitochondria. By virtue of these chimeric
signals at the N-terminus, xenobiotic-inducible cytochromes P4501A1,
2B1, 2E1 and 2D6 are targeted to both endoplasmic reticulum and
mitochondria [22–26]. The ﬁrst 35 amino acid residues of APP
resemble ER targeting signal, while 35–67 aminoacid sequence
resemble the mitochondrial targeting signal of cytochromes
P4501A1, 2B1 and 2E1 (Fig. 1B). Studies for the past decade showed
that the activation of mitochondrial signals hidden in the chimeric
signals of proteins is under the control of several physiological factors
such as proteases and phosphorylation. These factors likely vary from
protein to protein. For example, mitochondrial targeting signals of
P4501A1 are activated by soluble serine protease, which cleaves the
ER targeting domain of this protein [22,25]. In contrast, PKA-mediatedmical similarities of N-terminal 32 aminoacid sequence of human alpha synuclein with
al chimeric signals of P450 1A1, 2B1, 2E1 and 2D6 with N-terminus of APP comprising of
g domain.
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of cytochromes P4502B1 and 2E1, respectively [23,24].
Using in vitro mitochondrial import, in vivo transient transfection
and confocal immunoﬂuoroscence our laboratory showed that the
endogenous as well as ectopically expressed Alzheimer's full length
wild type and Swedish APP695 in HCN-1A neuronal cells are localized
to both plasma membrane and mitochondria [49]. Furthermore, the
positively charged residues at 40, 44, and 51 of APP are seemed to be
important for targeting to mitochondria [49]. Consistent with these
results, using biochemical and immunoﬂuorescence techniques
several reports have demonstrated that endogenous as well as
ectopically expressed APP forms are localized to mitochondria in
wide variety of cell lines such as PC12, COS, HEK 293, MEF cells [49–
52,54,55]. However, the mechanism by which hidden mitochondrial
targeting signals are activated in APP protein is unclear.
6. Interactions of alpha synuclein and APP with mitochondrial
import receptors
6.1. Interaction of alpha synuclein with import receptors
Mitochondrial localization of alpha synuclein seems to vary with
physiological conditions, cell lines and species [57–64]. Very limited
number of studies has focused on the involvement of mitochondrial
outer and inner membrane receptors in the import of alpha synuclein
[57–65]. However, recent study suggests that the interaction of alpha
synuclein with mitochondria is very selective and instant [113].
Furthermore, intra mitochondrial localization of α synuclein is
dependent on energy and membrane potential [57]. Using in vitro
import, it has been shown that the intra mitochondrial entry of alpha
synuclein is blocked by antibodies to outer membrane TOM40 protein
suggesting the requirement of general import pore forming TOM 40
protein [57]. In support of this, an interesting study using in vitro pull
down of mitochondrial proteins by synthetic C-terminal peptide of
alpha synuclein suggests the interaction of alpha synuclein with
TOM40 [65]. In addition, alpha synuclein is also reported to interact
with SAM 50, an outer membrane protein involved in the insertion of
beta barrel protein [65].
6.2. Interaction of APP with import receptors
Topology of mitochondrial full length APP as judged by limited
trypsin digestion is such that its NH2-terminus is located inside the
mitochondria while the COOH-terminal of the protein facing the
cytoplasmic side [49]. Nin–Cout orientation of mitochondrial APP was
further supported by using multiple biochemical and proteomic
approaches [54]. Furthermore, mitochondrially associated APP is a
non-glycosylated protein as opposed to plasma membrane associated
APP, which is glycosylated. Combination of chemical cross-linking and
immunoelectron microscopy study suggest that mitochondrial asso-
ciated APP is in contact with mitochondrial outer membrane (TOM20,
22 and 40) and inner membrane (TIM23) translocase proteins [49].
This is in contrast to the import mode of putative mitochondrial
proteins whose interactions with translocases are transient during
their entry in to mitochondria [97]. Additionally, acidic domain
spanning 220–290 amino acids of APP may be responsible for the
Nmito–Ccyto topology and the incomplete intra mitochondrial entry
resulting in the contact with import receptors [49]. This phenomenon
was also observed in the mitochondria of post mortem AD brains by
Blue-native gel electrophoresis coupled western blotting with anti-
bodies speciﬁc to import receptors, which showed outer membrane
TOM40 associated ∼480 and ∼620 kDa complexes and inner
membrane translocase TIM 23 associated ∼620 kDa complex [56].
These results suggest the possibility that mitochondrial APP may form
at least two different steady state import intermediates in AD brain
mitochondria.7. Sub mitochondrial localization of alpha synuclein and APP
7.1. Localization of alpha synuclein
Alpha synuclein is reported to be localized to outer membrane,
intermembrane space and inner membrane of mitochondria depend-
ing on species, cell lines and variations in the intracellular pH [57–
62,64]. Interestingly, under acidic conditions, ectopically expressed
alpha synuclein has been shown to localize exclusively to outer
membrane [62]. Studies have shown the constitutive presence of
alpha synuclein in mitochondria of rodents and humans [57,59–61].
Electron microscopy analysis suggest that constitutively expressed
alpha synuclein is exclusively localized to outer membrane in mouse
mitochondria [57,63], while outer and inner membranes of mitochon-
dria from rat and human brain show the immunoreactivity for alpha
synuclein [57,59–61]. In vitro imported alpha synuclein in the
presence of energy predominantly localizes to inner membrane [57].
In agreement with these studies, using sub-mitochondrial fractiona-
tion technique a recent study demonstrated that the in vitro
transported alpha synuclein was mainly accumulated in the inner
membrane of mitochondria [61]. However, the topology of mitochon-
drial alpha synuclein and the reason for its versatile sub-mitochon-
drial localization is not known.
7.2. Localization of APP
In vitro, neuronal cultures and human AD models show that full
length APP resides in mitochondria in Nin mito–Cout cyto orientation as
well as in close association with outer membrane channel forming
TOM40 protein [49,56]. However, ∼4 kDa abeta, a derivative of full
length APP is predominantly localized to inner membrane of
mitochondria [56,90,93,95,97,114].
8. Regional and cellular distribution of mitochondrial alpha
synuclein and APP under normal and disease status
The brain is a complex organ, with cellular, regional and functional
heterogeneity. Pathology of PD and AD that includes mitochondrial
dysfunction is regional and cellular speciﬁc. However, the cause for
regional and cellular speciﬁcity of these pathologies is not known.
Clearly, alpha synuclein and APP are implicated in the pathogenesis of
PD and AD, respectively. Furthermore, mitochondrial accumulation of
these proteins is associated with mitochondrial dysfunction in the
culture systems [49,52,53,57,59,62]. Thus, investigation of mitochon-
drial association of alpha synuclein and APP in different regions and
neurons in normal and disease brains may help in understanding the
regional and cellular speciﬁcity of these proteins in causingmitochon-
drial dysfunction during the pathogenesis of PD and AD.
8.1. Distribution of mitochondrial Alpha synuclein
Constitutive presence of alpha synuclein in themitochondria of brain
differs from region to region in rat and humans [57,60,61]. Mitochondria
from cerebellum and cortex have relatively lower levels of alpha
synuclein than hippocampus, striatum and substantia nigra [57,60,61].
However, alpha synuclein seems to be accumulating in the striatum,
substantia nigra and cortex of PD brains and these levels varies from 10
to 100ng/mgmitochondrial protein [57]. Dopaminergic neurons are the
most affected neuronal type in the PD. Ectopically expressed alpha
synuclein in dopaminergic DAN neurons accumulates in the mitochon-
dria compartment [57]. To test the presence of α synuclein in
mitochondria of dopaminergic neurons of PD brains, we carried out
using triple immuno staining on deparafﬁnised tissue sections from
postmortem substantia nigra (SN) of normal and PD subjects (obtained
from NDRI, Philadelphia according to institutional IRB approved
protocols and were characterized as described Ref # [57]) with
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were also stained with tyrosine hydroxylase (TH) antibodies to identify
dopaminergic neurons. In the SN of normal, a robust intracellular
staining of alpha synuclein antibodies (Fig. 2A) and TOM 20 (Fig. 2B)-
speciﬁc staining of particulate structures reminiscent of mitochondria
was observed. However, very little staining of α synuclein overlapped
withmitochondrial TOM20 staining in normal of SN (Fig. 2D) and some
of these neurons stained positively for TH antibody (Fig. 2C). However,
in the SN of PD, theα synuclein antibody stained appreciable amount of
extranuclear punctate structures (Fig. 2F) while TOM20 antibody
showed speciﬁc mitochondrial staining (Fig. 2G). Contrary to control,
extranuclear punctate structures ofα synuclein staining in the SN of PD
overlappedwith a signiﬁcant number ofmitochondrial TOM20 staining
(Fig. 2I) and some of these neurons also stained for TH antibody (Fig.
2H). These results suggest the presence of low levels of alpha synuclein
in the mitochondria of dopaminergic neurons of normal brain while in
the dopaminergic neurons of PD brain contains higher levels of alpha
synuclein.
8.2. Distribution of mitochondrial APP
APP immunoreactivity in the mitochondria from post mortem AD
brains (n=20) was higher than that of non-AD brains (n=20) [56].
Furthermore, accumulation of mitochondrial APP in AD brains is
dependent on the severity of the disease, which varied from region to
region. Using quantitative ELISA, it is estimated that mitochondrial APPFig. 2. Immunoﬂuorescence microscopy analysis of mitochondrial α synuclein in dopamin
dopaminergic neurons of substantia nigra of post mortem non-PD subject (NPS # 11) with an
of A and B. E = enlarged neuron. (F–J) Triple labeling of dopaminergic neurons of substantia
(G), and anti mouse TH (H). (I) Merged image of F and G. J = enlarged neuron. Immunostalevelswere in the range of 0.1 to 2.5 μg APP antibody reactive protein/mg
mitochondrial protein [56]. Interestingly, AD vulnerable brain regions
such as frontal cortex, hippocampus and amygdale showed higher
amounts ofmitochondrial APP inADbrains. However,mitochondrial APP
levels seem to be below detectable in non-AD brains [56]. Mitochondrial
accumulationofAPP indifferentneurons inADbrainalso showvariability
with respect to the severity of the disease. AD brains of all stages showed
the accumulation of APP in the mitochondria of cholinergic neurons
while mitochondrial APP accumulation was observed in dopaminergic,
GABAergic and glutamatergic of ADbrains belong to severe category [56].
Collectively, these results suggest that mitochondrial accumulation of
APP in various neuronal systems in different brain regions may have far
reaching inﬂuence on mitochondrial dysfunction that might inﬂuence
the neuronal survival in the pathogenesis of AD.
It is known that the presence of ApoE4 allele is considered to be
one of the risk factors in the pathogenesis of sporadic AD [115,116].
Studies have reported that apolipoprotein E (ApoE) genotypemay also
inﬂuence mitochondrial dysfunction [117]. Interestingly, majority of
AD subjects showed one or two ApoE4 alle and also possessed highest
amounts of mitochondrial APP [56]. Nevertheless, the precise
relationship between mitochondrial accumulation of APP and ApoE
genotyping in the pathogenesis of AD subjects is not known. However,
it is noteworthy to mention that recent studies have shownmutations
on TOM40 gene, which is located on the chromosome (19q) in close
proximity to upstream of ApoE, as a possible risk factor in the genesis
of AD [118,119]. Based on this, one can speculate that mutations onergic neurons of substantia nigra of non-PD and PD subjects. (A–E) Triple labeling of
ti rabbitα synuclein (A), anti goatTOM20 (B), and anti mouse TH (C). (D)Merged image
nigra of post mortem PD subject (#11) with anti rabbit α synuclein (F), anti goatTOM20
ining was carried out as described in Ref # [56]. Bar=100 μm.
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TOM40 protein, which may in turn accentuate the mitochondrial
translocational arrest of APP and associated mitochondrial dysfunc-
tion. However, it remains to be seen whether mutations render
impairment of TOM40 functions during the pathogenesis of AD.
9. Mitochondrial accumulation of synuclein and mitochondrial
dysfunction in cellular and human PD models
The involvement of alpha synuclein in bringing about the complex I
dysfunction in alpha synuclein linked PD or sporadic PD has been a
subject of intense investigation. Recent evidence suggest that alpha
synuclein andmitochondria interact with each other [57–65,113]. Lee et
al. [120] have also shown that an impaired mitochondrial function can
induce increased alpha synuclein expression and formation of alpha
synuclein inclusions. Alpha synuclein overexpression is also associated
with the release of cytochrome c, increase ofmitochondrial calcium and
nitric oxide, and oxidative modiﬁcation of mitochondrial components
[121,122]. Since increased expression of alpha synuclein and mitochon-
drial complex I deﬁciency are both implicated in PD pathogenesis, alpha
synuclein localization in mitochondria may indirectly suggest a
functional link between alpha synuclein and complex I.
Biochemical and immunoelectron microscopy data suggest that
mitochondria-localized alpha synuclein is predominantly associated
with inner membrane in the human and rat systems [57,61]. In DAN
cell culture system and under in vitro import conditions alpha
synuclein was shown to accumulate with time predominantly in the
inner mitochondrial membrane [57]. Interestingly, accumulation ofα-
synuclein in the mitochondria of human dopaminergic neurons
caused reduced mitochondrial complex I activity and increased
production of reactive oxygen species (ROS), whereas α-synuclein
lacking the mitochondrial targeting signal failed to associate with the
mitochondria and was not able to induce mitochondrial dysfunction
[57]. These results show a direct link between mitochondrial
accumulation of alpha synuclein and mitochondrial dysfunction.
Mitochondria from SN, striatum, and cerebellum of postmortem PD
patients and controls showed the constitutive presence ofα-synuclein
in the mitochondria of all three brain regions from normal subjects.
Interestingly, mitochondria isolated from SN and striatum but not
cerebellum from PD subjects showed signiﬁcant accumulation of α-
synuclein and decreased complex I activity [57]. Studies on the
incubation of alpha synuclein with isolated cerebellar and striatal
mitochondria show the inhibition of complex I activity [57,61].
Furthermore, this inhibition by alpha synuclein was dose-dependent,
with the minimal effective concentration being as low as 1 pM [61].
Blue-native gel electrophoresis and immunocapture analysis further
revealed the mitochondrial accumulated synuclein in both PD brains
and neuronal cultures were associated with holo complex I [57]. In
addition, these experiments also revealed the presence of sub
complexes of complex I. In support of these results a study using
proteomic approach also showed the interaction between alpha
synuclein and complex I subunits [65]. Recently, it has been shown
that the intricate assembly of complex I comprises the assembly of
small sub complexes to a holo complex I in a sequential manner [123].
However, it is not clear how alpha synuclein brings about the complex
I dysfunction either by preventing the assembly or by disrupting the
holo complex I. Nevertheless, these results for the ﬁrst time show a
direct connection between higher levels of mitochondrial synuclein
and complex I mediated mitochondrial dysfunction in the etiology of
PD. Alpha synuclein has been shown to interact with other
mitochondrial complexes. Using yeast two-hybrid study, wild type
alpha synuclein was found to interact with the mitochondrial
cytochrome c oxidase [124]. It was also reported that mutant (A53T)
alpha synuclein over-expressing transgenic mice developed mito-
chondrial degeneration as well as reduced complex IV activity [64].
Taken together, the above literature suggests that the backgroundlevels of mitochondrial alpha synuclein may be an important factor
inﬂuencing mitochondrial functions.
10. Implications of mitochondrial accumulation of full length APP
and its C-terminal product abeta in AD models
10.1. Mitochondrial accumulation of APP and mitochondrial dysfunction
Results from ours and other's laboratories have observed decreased
mitochondrial functions such as defects in oxidative phosphorylation,
decreased ATP, decreased membrane potential, and increased produc-
tion of ROS, perturbation in mitochondrial fusion and ﬁssion following
the mitochondrial association of full length APP in various cellular,
transgenic and human AD models [49–56]. Accumulation of full length
APP in themitochondrial compartment of cortex and hippocampuswas
observed in familial APP over-expressing Tg2576 mouse model
(12 months old), which is accompanied by decreased impaired
cytochrome c oxidase activity and decreased ATP level [49]. Decreased
cytochrome c oxidase activity, decreased ATP levels and increased nitric
oxide levels were also accompanied by mitochondrial accumulation of
APP in PC12 and HEK cells [49,52]. These abnormalities took place at a
faster rate inmodels expressingAPPwith familialmutations than inwild
type expressing models. Furthermore, mitochondrial accumulation of
APP and the associated mitochondrial abnormalities were progressive.
Consistent with animal and cellular models, mitochondria isolated
from theseADbrains showed increasedH2O2 levels, indicating impaired
cytochrome c oxidase activity, which was associated with transloca-
tionally arrested mitochondrial APP [56]. These studies indicate that
mitochondrial function may be a direct target for APP. However, the
expression of mitochondrial targeting mutant was accompanied by
reduced mitochondrial dysfunction suggesting the direct involvement
of mitochondrial accumulated APP in bringing about the some of the
mitochondrial anomalies. In addition, accumulation of APP lacking the
acidic domain was also accompanied by decreased mitochondrial
dysfunction implying the involvement of incomplete mitochondrial
translocation of APP mediated by the acidic domain spanning 220–290
amino acids of the protein in causing mitochondrial dysfunction [49]
Translocational arrest by acidic domain may result in the inhibition of
the import of proteins essential for normal mitochondrial functions. In
vitromitochondrial import using freshly isolatedmitochondria fromAD
brains showed the inhibition of cytochrome c oxidase subunits IV and
Vb [56]. The consequences of such inhibition under in vivo environment
may result in oxidative stress from perturbation of cytochrome c
oxidase. In support of the negative role associated with the acidic
domain, a study showed that intracellular accumulation of acidic
domain is capable of inducing cell death. However, the precise
mechanism for acidic domain mediated mitochondrial translocational
arrest in the pathogenesis of AD is unclear.
In contrast, constitutive low levels of APP in mitochondria are
important for maintaining mitochondrial functions [51]. Furthermore,
mitochondrial APP is reported to be interacting with complex V in
primary neuronal cultures [50]. Collectively, these studies suggest that
the like mitochondrial alpha synuclein, background concentration of
APP associated with mitochondria may play a critical role in
inﬂuencing mitochondrial functions.
10.2. Mitochondrial accumulation of Abeta and mitochondrial
dysfunction
Using immunoelectron microscopy, Yamaguchi et al. [125] for the
ﬁrst time reported the presence of immunoreactive Abeta in the
mitochondria of AD brains. A large number of studies using multiple
approaches have found ∼4 kDa Abeta in the mitochondria of
transgenic mouse, cellular and human AD models [56,90–97,114].
Very recently, Abeta is reported to be imported from outside into
mitochondria [94,114]. Using antibody inhibition technique, Hanson,
17L. Devi, H.K. Anandatheerthavarada / Biochimica et Biophysica Acta 1802 (2010) 11–19et al. [114] found that mitochondrial import of Abeta requires the
interaction with all major TOM proteins such as TOM20, TOM70 and
channel forming protein TOM40. Though in vitro imported Abeta is
localized to inner membrane of mitochondria interestingly, its import
is not dependent on mitochondrial membrane potential [114].
However, the presence of mitochondrial targeting signals in Abeta is
yet to be identiﬁed. Several reports have reported the role of
mitochondrial Abeta in affecting a wide variety of mitochondrial
functions [90–97]. In collaboration with Cu2+, Abeta was shown to
inhibit the cytochrome c oxidase activity in transgenic mouse models
[92]. Reddy and colleagues using various biochemical and cell
biological approaches have shown that Abeta can induce hydrogen
peroxide production, decreased cytochrome c oxidase activity,
synaptic dysfunction and increased formation of carbonyl proteins
in transgenic and cellularmodels of AD [48,87,90,126]. In addition, Yan
and colleagues showed that mitochondrial localized Aβ has been
directly shown to (a) inhibit Aβ binding alcohol dehydrogenase (b)
perturb mitochondrial permeability transition pore functions and (c)
impair enzymatic activities of respiratory chain complex III and IV
resulting in the reduced rate of oxygen consumption in transgenic
mouse and human AD models [93,95,97]. These studies collectively
suggest that Aβ localized to mitochondria may render mitochondria
vulnerable to oxidative damage by interacting with mitochondrial
proteins.
11. Concluding remarks
Physico-chemical properties of mitochondrial targeting signals of
alpha synuclein and APP share similarity with that of putative
mitochondrial signals. Though, these signals interact withmitochondrial
import receptors, the mechanisms by which these signals become fully
active are not clear. Studies show that accumulation of these proteins in
the mitochondrial compartment may bring about mitochondrial
dysfunction. The available literature suggests that the mitochondrial
targets for these proteins seem to be different. Mitochondrially
accumulated alpha synuclein may prefer to target complex I while APP
may prefer to target complex IV and importmachinery. It is important to
further investigate the mechanisms underlying sub-mitochondrial
localization of these proteins in order to understand their inﬂuence on
mitochondrial functions. Another note worthy point is that mitochon-
drial accumulation of these proteins in certain brain regions and neurons
may be an important factor in inducing mitochondrial abnormalities in
the pathogenesis of AD and PD. In conclusion, investigation of factors
responsible for the regional and cellular variations in the mitochondrial
targetingandaccumulation of theseproteinsmaybean important future
direction to unravel the mitochondrial dysfunction in AD and PD.
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